Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 25,186 shares at $18.13 ($348K) on 2021-01-04, disclosed to the SEC on 2021-01-06.
Open-market sale of $348k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 6,000 | $0 | 0.0% |
| 2 | $18.13 | 9,186 | $167K | 47.8% |
| 3 | $18.13 | 9,186 | $167K | 47.8% |
| 4 | $18.85 | 814 | $15K | 4.4% |
| Total | $13.83 avg | 25,186 | $348K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |